Skip to main navigation Skip to search Skip to main content

Incretin-Based Medications in Women and Reproduction: A Systematic Scoping Review and Consensus Guidelines for Clinical Practice

  • Kate Maslin*
  • , Jill Shawe
  • , Sinead Blowers
  • , Michael Ceulemans
  • , Kathryn Hart
  • , Sam Schoenmakers
  • , Amihai Rottenstreich
  • , Heather Hopper
  • , Mojca Jensterle
  • , Angela C. Flynn
  • , Sarah Siegelaar
  • , Annick Bogaerts
  • , Isy Douek
  • , Nicola Heslehurst
  • , Dries Ceulemans
  • , Tricia Tan
  • , Johnathan Pinkney
  • , Martin Whyte
  • , Shahrad Taheri
  • , Roland Devlieger
  • *Corresponding author for this work
  • REALIFE Research Group
  • KU Leuven
  • Royal Cornwall Hospitals NHS Trust
  • University of Plymouth
  • Belgian National Fund for Scientific Research
  • University of Surrey
  • Erasmus University Rotterdam
  • Edith Wolfson Medical Center Israel
  • Tel Aviv University
  • University Hospitals Plymouth NHS Trust
  • University of Ljubljana
  • Royal College of Surgeons in Ireland
  • Amsterdam UMC
  • Somerset NHS Foundation Trust
  • Newcastle University
  • Imperial College London
  • Marshall University

Research output: Contribution to journalReview articlepeer-review

1 Downloads (Pure)

Abstract

Introduction: Pregnancy concurrent with incretin-based medications is contraindicated due to unknown risk of teratogenicity, as is breastfeeding. The aim of this systematic scoping review was to investigate potential risks and benefits of incretin-based medications in relation to preconception, pregnancy, and postnatal health, and to propose expert guidelines for clinical practice.

Methods: An international expert multidisciplinary group was formed. Research questions relevant to women's reproductive health and incretin-based medications were refined collaboratively, utilizing a lifecourse approach. A systematic search was undertaken on July 23, 2025, across several databases and grey literature sources. Primary data from human studies were prioritized above animal studies. Titles, abstracts, and full text articles were screened independently by two authors. Data were extracted by two people independently using a pre-defined proforma and synthesized narratively. Consensus recommendations were made.

Results: Thirty-four articles were included in the evidence synthesis: 11 randomized trials, nine observational studies, two pharmacovigilance reviews, nine case reports/series, two animal studies, and one ex vivo study. No qualitative studies were identified. Evidence was found for 18/32 (56.3%) research questions. Most studies related to preconception or pregnancy usage; two addressed contraception, and one was about lactation. The sample size of exposed pregnancies ranged from 1 to 4267. Three studies reported exposure throughout pregnancy. Three studies investigated postpartum usage. One (animal) study had offspring data beyond birth. No studies reported an increase in congenital anomalies.

Conclusion: Clinical practice and research recommendations were made based on current available evidence and evidence gaps, encompassing contraception, preconception, nutritional, pregnancy monitoring, lactation, and longer-term outcomes.
Original languageEnglish
Article numbere70203
JournalObesity Reviews
Early online date29 Jul 2026
DOIs
Publication statusPublished - 29 Jul 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Public Health, Environmental and Occupational Health

Keywords

  • GLP‐1
  • fetal
  • incretin
  • maternal
  • obesity
  • postpartum
  • preconception
  • pregnancy

Fingerprint

Dive into the research topics of 'Incretin-Based Medications in Women and Reproduction: A Systematic Scoping Review and Consensus Guidelines for Clinical Practice'. Together they form a unique fingerprint.

Cite this